Medicare Advantage Premiums Fall While Benefits Shrink: KFF Spotlight Exposes the Actuarial Trade-Off

From analyzing MA bid data and benefit filing patterns across 15 major plan sponsors over the past five plan years, the current premium-down, benefits-down pattern is a classic late-cycle margin management move. It signals deeper structural pressure ahead. The trade press treated KFF's 2026 Spotlight as broadly positive: premiums are falling. But anyone who has built an MA bid knows that the premium line is the last place plans cut. It is where they invest to retain enrollment while quietly reducing benefit value elsewhere in the bid structure. The premium buys a marketing headline. The benefit cuts buy solvency.

KFF's data, combined with Milliman's Medicare Advantage Competitive Value-Added Tool (MACVAT) and CMS enrollment filings, paints a picture that is far less reassuring than the headline premium decline suggests. Medicare Advantage plans reduced supplemental benefits at the fastest pace in program history while simultaneously lowering premiums, a combination that only makes sense when viewed through the mechanics of the Part C bid process and the compounding rate pressures that are reshaping MA plan economics.

What the KFF 2026 Spotlight Actually Shows

KFF's annual Medicare Advantage Spotlight provides the most widely cited first-look at plan premiums and benefit offerings across the MA market. The 2026 edition documents a market-wide pattern: average monthly premiums declined from $16.40 to $14.00, while supplemental benefits were trimmed across nearly every non-core category.

The supplemental benefit reductions span the categories that plans have used for the past decade to differentiate MA from traditional Medicare:

• Over-the-counter allowances: Offered by 66% of plans in 2026, down from 73% in 2025. OTC allowances have been among the most-used supplemental benefits in MA, with average monthly values that ranged from $30 to $150 depending on the plan.
• Meal benefits: Down from 65% of plans to 57%. Post-discharge and chronic condition meal programs were a key differentiator for plans targeting high-acuity enrollees.
• Transportation services: Declined from 30% to 24%. Non-emergency medical transportation helps beneficiaries access care, and its removal disproportionately affects rural and low-income enrollees.
• Remote access technologies: Fell from 53% to 48%. Telehealth and remote monitoring capabilities that expanded during the pandemic are being scaled back as plans tighten spending.

Vision, dental, and hearing coverage remained near-universal at 98% or above, but the depth of those benefits has thinned. Annual dental allowances have declined at many carriers, and vision benefit maximums have been reduced even as the coverage category itself persists. These core supplemental benefits are too deeply associated with MA's value proposition to eliminate, but their generosity is eroding at the margins.

The number of zero-premium MA-PD plans, long the most visible marketing advantage of Medicare Advantage, declined by 231 plans for 2026, a 9.5% reduction. For potential enrollees comparing options during open enrollment, fewer zero-premium plans mean fewer obvious reasons to choose MA over traditional Medicare with a Medigap supplement.

Inside the MA Bid Mechanic: Where Premiums and Benefits Compete

The premium-down, benefits-down pattern becomes legible only when you understand the MA bid process, which is the single most consequential actuarial exercise in Medicare Advantage economics.

Each year, MA plan actuaries submit a bid to CMS representing the plan's projected cost of covering the standard Part A and Part B benefit package for an average enrollee. CMS compares this bid to a county-level benchmark derived from fee-for-service Medicare spending. What happens next depends on the relationship between the bid and the benchmark:

• If the plan bids below the benchmark, it receives a rebate equal to a percentage of the difference. The rebate percentage depends on the plan's Star Rating: 50% for plans rated below 3.5 stars, 65% for plans rated 3.5 stars, and 75% for plans rated 4.0 stars or above.
• If the plan bids above the benchmark, the enrollee pays the difference as an additional premium on top of the Part B premium.

The rebate is the revenue source that funds everything distinctive about MA. Plans must allocate rebate dollars across three competing uses: premium buy-down (reducing the member's monthly premium toward or below zero), supplemental benefits (dental, vision, OTC, meals, transportation), and Part D cost reduction. This is a zero-sum allocation. Every dollar used to buy down premiums is a dollar unavailable for supplemental benefits, and vice versa.

The observed 2026 pattern, where plans lowered premiums while cutting supplemental benefits, reveals a deliberate allocation choice. Plan actuaries shifted rebate dollars toward premium buy-down and away from supplemental benefit funding. The logic is strategic: a lower premium is the most visible attribute during annual enrollment period comparison shopping. Supplemental benefit reductions are harder for enrollees to evaluate in advance and typically only become apparent after the coverage year begins, when the OTC allowance is gone or the meal benefit has disappeared.

This is not deception. It is a rational response to shrinking total rebate pools. When the rebate itself is declining due to benchmark compression, risk adjustment cuts, or Star Rating downgrades, plan actuaries must choose which line items to protect. Protecting the premium protects enrollment. Cutting supplemental benefits preserves plan-level solvency. Both are actuarially defensible priorities; the question is which one an individual plan's competitive position demands.

Quantifying the Benefit Value Decline

Milliman's MACVAT analysis provides the most granular actuarial measurement of how benefit richness changed from 2025 to 2026. Their general enrollment study documented a greater than 7% decline in total value added across the MA market, the largest single-year drop in the tool's history.

The components of that decline tell a specific story about where plan actuaries chose to absorb margin pressure:

• Part C benefit value decreased approximately $17 per member per month, reflecting higher cost-sharing imposed on members for medical services covered under the standard A/B benefit structure.
• Part D benefit value decreased approximately $4 PMPM, driven substantially by the Inflation Reduction Act's Part D redesign that shifted catastrophic coverage costs from Medicare to plans.
• Average medical maximum out-of-pocket (MOOP) rose from $5,100 to $5,440, a 7% increase that directly increases enrollees' worst-case annual exposure.
• Medical deductibles increased from $33 to $57, a 72% increase that introduces first-dollar cost-sharing for services that were previously covered from the first claim.
• Part D deductibles increased from approximately $230 to $375. The share of enrollees facing Part D deductibles exploded from 23% in 2024 to 83% in 2026, transforming what was once an uncommon feature into the default plan design.

Milliman also observed that carriers with declining value added experienced enrollment losses of 4% to 33%, while one carrier that improved its value-added position saw 22% enrollment growth. The market is pricing benefit cuts into enrollment decisions in real time. Plans that cut too deeply lose members. Plans that do not cut enough lose margins. The actuarial optimization problem is finding the inflection point between those two outcomes.

Three Layers of CMS Rate Pressure Compounding Simultaneously

The benefit erosion documented by KFF and Milliman is the downstream consequence of three distinct CMS policy actions compressing plan revenue at the same time. Each would be manageable in isolation. Together, they create the structural pressure that is forcing the premium-benefit trade-off into the open.

Layer 1: V28 risk adjustment completion

The CMS-HCC risk adjustment model completed its transition to Version 28 for payment year 2026, finishing a three-year phase-in (33% V28 in PY 2024, 67% in PY 2025, 100% in PY 2026). V28 reduced the number of valid diagnostic codes from 9,797 under V24 to 7,770, eliminating diagnoses that CMS determined were weak cost predictors or were subject to systematic coding inflation. CMS projected the change would reduce average MA risk scores by 3.12%, representing approximately $11 billion in reduced payments to plans across the industry.

The revenue hit from V28 is not uniformly distributed. Plans with concentrated chronic-condition populations whose diagnoses mapped to eliminated or reweighted Hierarchical Condition Categories (HCCs) face effective risk score declines of 4% to 5% on specific sub-populations, well above the 3.12% average. Plans that relied on broad diagnostic coding to maintain risk scores above the actuarially indicated level are absorbing disproportionate losses.

Layer 2: chart review exclusion

CMS proposed in the CY 2027 Advance Notice to exclude unlinked chart review diagnoses from MA risk scores, targeting an estimated $7.12 billion in annual payments. Unlinked chart reviews are retrospective medical record audits conducted by plans to identify diagnoses that were present but not captured in provider encounter data. CMS argues these diagnoses, because they were not documented during a face-to-face clinical encounter, are more likely to reflect coding intensity than genuine clinical complexity.

MedPAC supported the exclusion in its February 2026 comment letter, framing it as a necessary correction to the diagnostic coding practices that have inflated MA risk scores for more than a decade. STAT News reported that CMS is using "fresher data" to rein in upcoding, referencing the agency's shift toward more contemporaneous encounter data as the basis for risk adjustment calculations.

For plan actuaries building 2027 bids, the chart review exclusion creates a binary exposure. Plans that derive a significant share of their risk adjustment revenue from retrospective chart reviews face a discrete revenue cliff. Plans that have invested in point-of-care coding accuracy, prospective provider education, and natural language processing tools to capture diagnoses during clinical encounters are better positioned to absorb the change.

Layer 3: rate compression

The CMS 2027 final rate of 2.48% represented a substantial improvement from the 0.09% proposed in the advance notice, a 239-basis-point swing that reflected revised fee-for-service normalization, V28 risk score trend adjustments, and the Star Ratings methodology overhaul. But 2.48% still falls well short of the 6% to 8% medical trend most industry actuaries project for MA populations in 2026 and 2027.

The rate-to-trend gap means that even with the improved 2027 rate, plans cannot maintain current benefit levels without finding margin elsewhere. Network renegotiations, administrative cost reductions, and utilization management tightening are all in play, but benefit design remains the fastest and most controllable lever available to plan actuaries operating under bid filing deadlines.

Four Carriers Control the Benefit Design for 71% of Enrollees

Enrollment concentration in Medicare Advantage means that benefit design choices at four organizations propagate across the majority of the market. UnitedHealthcare, Humana, CVS Health (Aetna), and Elevance Health (Anthem) together enroll approximately 24 million of the program's 34 million beneficiaries. When these four carriers adjust supplemental benefits, deductibles, or cost-sharing structures, the changes affect tens of millions of enrollees and set competitive benchmarks that smaller plans must respond to.

UnitedHealthcare remains the largest MA carrier by enrollment despite pulling back from 109 counties for 2026. UHC's scale gives it negotiating leverage with provider networks that smaller competitors cannot match, allowing it to maintain somewhat richer benefits in markets where it competes head-to-head with Humana or Aetna. Even so, UHC has raised MOOP limits and trimmed OTC allowances across multiple plan offerings for 2026.

Humana faces the most acute pressure of the four. Its largest MA contract, covering roughly 45% of its enrollment, dropped from 4.5 to 3.5 stars between the 2025 and 2026 rating years. That one-point decline stripped quality bonus eligibility from millions of enrollees, reducing the rebate percentage from 75% to 65% and shrinking the total rebate pool available for benefits and premium buy-down. Combined with its exit from 194 counties and three states, Humana's benefit design choices for 2026 reflect a carrier in active portfolio rationalization.

CVS Health (Aetna) discontinued approximately 90 MA plans across 34 states for 2026, with the majority being PPO products. PPOs carry structurally higher medical loss ratios than HMOs because out-of-network utilization is harder to manage. Aetna's selective PPO exits signal that the PPO product form is becoming economically unviable in lower-benchmark counties under the current rate environment.

Elevance Health has pursued a comparatively smaller geographic pullback but has aggressively shifted enrollment toward Dual-Eligible Special Needs Plans (D-SNPs), which carry higher per-member benchmarks and qualifying for risk adjustment coefficients that general enrollment plans do not receive. Elevance's strategy illustrates an alternative response to rate pressure: rather than cutting benefits across the general enrollment portfolio, pivot product mix toward higher-margin segments.

The concentration dynamic creates a feedback loop. When UHC and Humana cut OTC allowances, smaller regional plans face a choice: match the cut and maintain competitive premiums, or maintain the benefit and accept a higher premium that may cost enrollment. In practice, most regional plans follow the large carriers' lead within one to two plan years, amplifying the benefit erosion across the market.

The $14 Premium Is Not a Discount

CMS's headline that average MA premiums declined from $16.40 to $14.00 per month framed the number as evidence of continued MA value. That framing misses the full cost picture.

Consider an enrollee who used a plan's $75-per-month OTC allowance in 2025. If that allowance is eliminated for 2026, the enrollee saves $2.40 per month on premiums but loses $75 per month in OTC benefit value. The net effect is a $72.60 monthly cost increase. For enrollees who relied on meal benefits, transportation, or other eliminated supplemental services, similar calculations apply. The premium decline is real but small; the benefit reductions, measured in actual enrollee spending impact, are substantially larger.

For plan actuaries, the shift from premium-funded to cost-sharing-funded plan designs also changes the utilization distribution. Higher medical deductibles and the dramatic expansion of Part D deductible exposure (from 23% to 83% of enrollees in two years) introduce first-dollar cost-sharing where none previously existed. Actuarial literature consistently finds that increased cost-sharing reduces utilization in the short term, particularly for discretionary and preventive services. The long-term cost implications are less clear: deferred preventive care can produce higher-severity claims downstream.

The 72% jump in medical deductibles (from $33 to $57) and the 7% MOOP increase (from $5,100 to $5,440) are individually modest in dollar terms. But they compound with the supplemental benefit reductions to shift a material share of healthcare spending from plan to enrollee. From tracking MA benefit filings over multiple plan years, this is the inflection point where the value proposition of MA relative to traditional Medicare with a Medigap supplement starts to narrow for the healthiest segment of the enrolled population, exactly the members whose retention determines plan-level risk selection.

Plan Exits Amplify the Benefit Erosion

The benefit reductions documented by KFF are occurring against a backdrop of unprecedented plan exits. As we analyzed in our coverage of the 2026 disenrollment wave, approximately 2.9 million MA enrollees were forced to switch plans for 2026 after their carriers exited their counties, a rate of roughly 10% compared to a historical average below 2%.

Plan exits and benefit erosion reinforce each other through several mechanisms. Carriers that exited counties did so because bid economics were no longer viable in those geographies. The remaining plans in those counties absorbed displaced enrollees, but they did so on the same compressed rate environment that drove the exits. The result: surviving plans in high-exit counties often offered thinner benefits than the plans they replaced, because the same economic forces applied.

For the roughly 2.9 million displaced enrollees, the combination of forced plan switching and benefit erosion in their new plans creates a compounded disruption. They lost their existing plan, enrolled in a new plan with reduced supplemental benefits, and face higher cost-sharing under a design they did not choose. CMS projects total MA enrollment at 34 million for 2026, down from 34.9 million in 2025, with the MA share of total Medicare declining from 50% to approximately 48%. Some of the enrollment decline reflects beneficiaries who, after experiencing both plan exits and benefit cuts, concluded that traditional Medicare offered more stability.

Actuarial Implications and What the Bid Data Signals